human F9 gene therapy (LogicBio Therapeutics/NIH/University of Sydney/Stanford University School of Medicine)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namehuman F9 gene therapy (LogicBio Therapeutics/NIH/University of Sydney/Stanford University School of Medicine)
Drug Alias NameAAV-DJ GeneRide vectorLB-101 (LogicBio Therapeutics)
ClassificationBiologics
Mechanisms of ActionCoagulation factor IX stimulants
TargetsCoagulation factor IX
Therapy Area/IndicationsHemophilia BMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia and New Zealand
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesLogicbio Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLogicbio Therapeutics IncNational Institutes Of HealthStanford University School of Medicine +[4] 
Active IndicationsN/A
Inactive IndicationsHemophilia BMetabolic Dysfunction-Associated Steatotic Liver Disease

Other Information

ATC CodeN/A
Related LinksN/A